Education
About Us
Working with TipRanks
Follow Us
Lisata Therapeutics (LSTA)
NASDAQ:LSTA
Earnings Data
Report Date
Aug 18, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.64Last Year’s EPS
-0.61Same Quarter Last Year
Moderate Buy
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 5.49%
|Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and financial management improvements, despite some delays and challenges in strategic partnerships and trial enrollments. The company's focus on advancing Certepetide through various trials and securing regulatory designations indicates a strong strategic direction.Company Guidance
During the Lisata Therapeutics First Quarter 2025 Financial Results and Business Update Conference Call, the management team provided extensive guidance on the company's strategic plans and financial metrics. Operating expenses for the quarter totaled $5.8 million, a reduction of $0.8 million or 11.4% year-over-year. Research and development expenses decreased by 19.7% to $2.6 million, while general and administrative expenses saw a modest decline of 3.4% to $3.2 million. The company reported a net loss of $4.7 million, down from $5.4 million the previous year. Lisata holds approximately $25.8 million in cash, cash equivalents, and marketable securities, which is expected to support operations into Q3 2026. The company is advancing its clinical development portfolio, particularly focusing on the product candidate Certepetide targeting advanced solid tumors. Key upcoming milestones include data from Cohort B of the ASCEND trial at the 2025 ESMO GI Congress in July and accelerated data readout from the Bolster trial in mid-2025. Additionally, a $10 million milestone payment is anticipated from Qilu Pharmaceutical upon the first patient dosing in their Phase 3 study of Certepetide.Decreased Operating Expenses
Operating expenses for Q1 2025 were $5.8 million, an 11.4% decrease from $6.6 million in Q1 2024, driven by lower clinical research and administrative costs.
Significant Progress in Clinical Trials
Lisata has advanced its clinical development portfolio, particularly with its product candidate Certepetide, which showed promising preliminary results in various trials, including ASCEND and Bolster.
Improved Financial Position
Lisata reported a net loss of $4.7 million for Q1 2025, compared to $5.4 million in Q1 2024, indicating improved financial management.
Secured Special Regulatory Designations
Certepetide received multiple special designations from the FDA and EMA, enhancing its regulatory standing and potential market entry.
Positive Preliminary Cohort A Data
Preliminary data from the ASCEND trial showed a positive trend in overall survival and complete responses in the Certepetide-treated group.
LSTA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
LSTA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $2.37 | $2.10 | -11.39% |
Feb 27, 2025 | $2.40 | $2.38 | -0.83% |
Nov 12, 2024 | $2.91 | $2.79 | -4.12% |
Aug 12, 2024 | $2.93 | $2.94 | +0.34% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Lisata Therapeutics (LSTA) report earnings?
Lisata Therapeutics (LSTA) is schdueled to report earning on Aug 18, 2025, TBA Not Confirmed.
What is Lisata Therapeutics (LSTA) earnings time?
Lisata Therapeutics (LSTA) earnings time is at Aug 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LSTA EPS forecast?
LSTA EPS forecast for the fiscal quarter 2025 (Q2) is -0.64.